CJC-1295

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, engineered to resist breakdown and — in the DAC form — to bind albumin so it stays active for days. Early human trials showed it raises growth hormone and IGF-1. What no trial has shown is that raising those markers produces the body-composition, recovery or anti-ageing outcomes it is marketed for. In Australia it is unregistered, prescription-only, and prohibited in sport.

What CJC-1295 is

CJC-1295 is a synthetic peptide modelled on growth-hormone-releasing hormone (GHRH) — the signal the hypothalamus sends the pituitary telling it to release growth hormone (GH).

Natural GHRH is fragile: it is cleaved within minutes by an enzyme called DPP-IV, exactly what you would want from a signal that has to switch off. CJC-1295 is a re-engineered version of the biologically active first 29 amino acids of GHRH, carrying substitutions that resist that cleavage — a form often called modified GRF (1-29).

Two versions are discussed, and conflating them causes most of the confusion online:

• CJC-1295 with DAC. DAC stands for Drug Affinity Complex — a linker that bonds the peptide to albumin, the most abundant protein in blood. Tethered there, it is shielded from clearance and circulates for days rather than minutes. Essentially all published human data relate to this form.
• CJC-1295 without DAC, sold as "Mod GRF 1-29" — the same DPP-IV-resistant sequence without the albumin linker. Far shorter-acting, with no meaningful human trial literature of its own.

CJC-1295 is not an approved medicine anywhere. In Australia it is prescription-only, supplied if at all as a compounded preparation. It is most often discussed alongside ipamorelin, which acts on an entirely different receptor — see our guide to GH peptides in Australia.

How it works

The normal system is pulsatile, and that is not an accident. The pituitary releases GH in bursts, heavily concentrated in deep sleep, under the opposing control of GHRH, which drives release, and somatostatin, which suppresses it. Between pulses, GH falls to very low levels. Tissues appear to respond to that pattern — peaks and troughs — rather than to the average amount present, so any drug altering GH release is altering a rhythm, not just a level.

CJC-1295 binds the GHRH receptor on pituitary somatotroph cells, mimicking that release signal. Because it resists DPP-IV, and because the DAC form is tethered to albumin, the signal persists for a very long time by the standards of the system it imitates.

One reassuring finding, one open question. In the published human work, prolonged GHRH-receptor stimulation did not flatten GH release into a continuous elevation — pulsatility was largely preserved, with the pulses raised. That mattered, because a drug abolishing pulsatility would be a poor mimic of physiology. Whether raising the pattern week after week has the same consequences as the body's own signalling is unanswered.

Downstream comes IGF-1. GH acts partly directly and partly through insulin-like growth factor 1, produced mainly by the liver. IGF-1 mediates much of GH's tissue action and — being stable in blood, unlike pulsatile GH — it is what clinicians actually measure. That convenience is also the source of the central error in how these compounds are marketed.

A note on what this is not. CJC-1295 asks the pituitary to release its own GH; if the pituitary cannot do that, it will not work. Genuine adult growth hormone deficiency is a specific endocrine diagnosis made by a specialist using dynamic stimulation testing, and it is treated with registered growth hormone products.

What the human evidence actually shows

The pharmacology is real. The outcomes have never been tested. That is the whole of it, and it is worth unpacking.

What the trials showed. The most-cited human data come from early-phase work in healthy adults — most notably a randomised, placebo-controlled study (Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism, 2006). It reported that single subcutaneous administrations of the DAC form produced dose-dependent increases in GH lasting several days and in IGF-1 lasting well over a week, and that it was generally well tolerated over the short period studied.

What those trials were designed to do. Establish pharmacokinetics, pharmacodynamics and short-term tolerability in small numbers of healthy volunteers — which is what phase 1 is for. They were not sized or long enough to determine whether anything useful happens to a person as a result.

Raising GH and IGF-1 is a biomarker, not an outcome. This is the point most marketing in this category depends on. A blood test moving in the desired direction is not a benefit. Fat mass, lean mass, strength, recovery time, sleep quality, cardiovascular risk — those are outcomes. Medicine is littered with drugs that moved a marker convincingly and then failed to improve, or actively worsened, the thing the marker stood for. A rising IGF-1 result proves the compound is pharmacologically active. It proves nothing about whether you are better off.

No large or long-term trials exist. There is no substantial randomised evidence for CJC-1295 improving body composition, performance, recovery or any ageing-related outcome, and no long-term safety data. Development did not proceed to registration, and no CJC-1295 product is approved as a medicine anywhere.

The popular stack is unvalidated. CJC-1295 with ipamorelin is the most promoted arrangement in this space, and the rationale — two receptors, complementary signals — is coherent. But the combination has never been evaluated in a human outcome trial, for effectiveness or safety. Two individually unproven compounds make an unproven combination, not a proven one.

A properly proven comparator looks different. Tesamorelin, another GHRH analogue, went through full clinical development for one defined medical condition and achieved registration in some markets on that basis. CJC-1295 has not been through anything like it.

The honest summary: a well-designed molecule that reliably does what it was engineered to do to a blood test, with no demonstration that doing so helps anyone.

Regulatory status in Australia

CJC-1295 is not on the Australian Register of Therapeutic Goods and is handled as a prescription-only (Schedule 4) substance. It has not been evaluated by the TGA, and there is no TGA-approved Product Information — no approved indication, no approved contraindications, no evaluated interaction data.

Where it is supplied here, it is as a compounded preparation made for an individual patient against a prescription. That route is lawful, but it is not registration:

• The preparation has not been assessed by the TGA.
• Identity, purity, sterility and batch consistency depend on the compounding pharmacy's own quality systems.
• There is no post-market safety surveillance of the kind registered medicines carry.

Buying it from an overseas website, a "research chemical" supplier or any direct-to-consumer source is unlawful and unsafe, with no assurance of what the vial contains — see our explainers on peptide legality in Australia and compounded versus TGA-registered medicines. Prescription-only medicines also cannot be advertised to the public here, so a clinic promoting this compound with claimed benefits is not operating the way the rules intend.

Anti-doping status

CJC-1295 is prohibited at all times in sport under the WADA Prohibited List, category S2 — peptide hormones, growth factors and mimetics — which explicitly covers GHRH and its analogues. Sport Integrity Australia applies the same list. This binds every athlete under an anti-doping code, not only elite competitors, and applies whether or not the compound was prescribed.

Who it is being studied for — and who it is not for

Clinical interest in GHRH analogues as a class has been in defined medical problems — diagnosed growth hormone deficiency, specific wasting and fat-redistribution syndromes — where there is a measurable pathology to correct. Interest in CJC-1295 for body composition, recovery, sleep and ageing in healthy adults is mechanistically motivated and commercially driven, not trial-supported.

Circumstances where a careful practitioner would be especially cautious, or would decline, include pregnancy and breastfeeding, active or previous malignancy, diabetes or impaired glucose tolerance, untreated sleep apnoea, and pituitary disease.

Two merit expansion. Glucose regulation: growth hormone opposes insulin, and sustained elevation is associated with insulin resistance, which puts anyone with diabetes or prediabetes in a different risk category. Cancer: IGF-1 signalling promotes cell proliferation and suppresses programmed cell death, so persistently raising it in someone with a current or past malignancy requires specialist input, not a wellness consultation.

And the ordinary point that gets skipped: fatigue, poor recovery and stubborn body composition have common, investigable causes — sleep disorders, iron and thyroid problems, depression, alcohol, badly managed training load. If a clinic proposes a GH peptide before anyone has looked at your bloods, the compound came first and the reasoning was fitted around it.

Risks and considerations

Because no long-term human data exist, the risk picture is assembled from short trials, clinical experience, and what is known about growth hormone excess generally. That last source is informative: acromegaly, the disease of chronic GH excess, brings fluid retention, joint pain, carpal tunnel syndrome, impaired glucose handling, hypertension and cardiac change. Nobody suggests a compounded peptide produces acromegaly — the point is that the direction of effect is known, and not uniformly benign.

Reported and theoretically expected effects include:

• injection-site reactions — redness, itching, swelling, bruising
• fluid retention, puffiness and joint aches
• tingling or numbness in the hands
• headache, flushing and dizziness
• disturbance of blood-sugar regulation
• the theoretical IGF-1 concern described above

Beyond side effects: it is an injectable, requiring competent technique and safe sharps handling, and any product from outside the regulated supply chain adds purity, potency and sterility risks on top of the pharmacological ones. Anything unexpected goes to your treating practitioner promptly.

What to ask a doctor

• What problem are we treating, and how was it diagnosed?
• Have the ordinary causes — sleep, iron, thyroid, mood, training load, alcohol — been investigated first?
• If growth hormone deficiency is suggested, has it been formally tested by an endocrinologist?
• No trial has shown CJC-1295 improves any real-world outcome. What is this recommendation based on?
• Which pharmacy compounds it, and what quality accreditation do they hold?
• Are we treating my symptoms or my blood test, and what will you measure?
• What counts as this working, by when, and what is the stopping rule if it is not?
• How will my blood sugar be monitored, and is my cancer history relevant here?
• If I compete in a tested sport, what does this do to my anti-doping status?
• What does the full course cost, including consultations, pathology and follow-up?

FAQ

Is CJC-1295 approved in Australia? No. It is prescription-only (Schedule 4) and not on the ARTG. Lawful access is only through a registered practitioner and a compounding pharmacy.

What is the difference between CJC-1295 with and without DAC? The DAC form carries a linker that bonds to albumin, keeping it active for days. The non-DAC form ("Mod GRF 1-29") lacks it and is much shorter-acting. Almost all published human data relate to the DAC version, so evidence claims about "CJC-1295" generally do not apply to the non-DAC product.

Does it build muscle or burn fat? Unproven. Early trials established that it raises GH and IGF-1. No adequate trial has shown this translates into meaningful changes in muscle, fat, strength or performance.

My IGF-1 went up — doesn't that prove it works? It proves the compound is pharmacologically active, not that it benefits you. Surrogate markers have repeatedly failed to predict real outcomes across medicine. The question is whether you are measurably better, not whether a number is.

Why is it so often combined with ipamorelin? Because they act on two different receptors — GHRH and the ghrelin receptor — and the signals are theorised to be complementary. The theory is coherent; the combination has never been validated in a human outcome trial.

Is it the same as taking growth hormone? No. Synthetic GH replaces the hormone directly; CJC-1295 asks your own pituitary to release more. Both are prohibited in sport and both carry GH-related risks.

Should I look for a clinic that offers it? Start with the problem, not the compound. A practitioner worth seeing will investigate why you feel the way you do before reaching for an unregistered peptide. You can check a prescriber's AHPRA registration before any consultation, and compare doctor-supervised muscle and performance clinics once you know what you are looking for.